SCHEMBL364360

SCHEMBL364360

COC(=O)c1cc(Br)c(Oc2ccc(Cl)cc2)cc1F

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
PNLIP P16233 5/20 0.43
TDP1 Q9NUW8 1/20 0.43
CCNC P24863 1/20 0.43
CDK8 P49336 1/20 0.43
SLC1A3 P43003 1/20 0.41
SLC1A2 P43004 1/20 0.41
SLC1A1 P43005 1/20 0.41
KMT2A Q03164 1/20 0.41
ABL1 P00519 1/20 0.41
SCN9A Q15858 3/20 0.41
P2RX3 P56373 2/20 0.41
EPAS1 Q99814 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
SLC6A4 P31645 1/20 0.40
SLC6A3 Q01959 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL364314 0.84 MEN1 (0.46) LMNAKMT2AABL1EPAS1SLC6A4
SCHEMBL17185192 0.83 LMNA (0.46) LMNAPNLIPTDP1CCNCCDK8
SCHEMBL17185349 0.81 HTR2A (0.42) LMNAPNLIPTDP1CCNCCDK8
SCHEMBL17996051 0.79 P2RX3 (0.55) LMNATDP1ABL1SCN9AP2RX3
SCHEMBL4206479 0.78 SOS1 (0.47) LMNASLC6A4SLC6A3
SCHEMBL364231 0.77 USP2 (0.49) LMNAPNLIPCCNCCDK8KMT2A
SCHEMBL12765104 0.77 CCNC (0.48) LMNAPNLIPTDP1CCNCCDK8
SCHEMBL19463898 0.76 GCK (0.40) LMNASLC1A3SLC1A2SLC1A1KMT2A
SCHEMBL3337570 0.75 SOS1 (0.47) LMNAKMT2AABL1
SCHEMBL21544808 0.75 SOS1 (0.39) LMNASLC1A3SLC1A2SLC1A1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593433-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-26 EP disclosed
EP-2593433-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-26 EP disclosed
US-8772343-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
US-8772343-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
US-8772343-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 US disclosed
EP-2593433-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130116285-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-09 US disclosed
US-20130116285-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-09 US disclosed
US-20130116285-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-09 US disclosed
WO-2012007877-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed
WO-2012007877-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116285-A1 Chemical Compounds SCN1A, SCN10A, SCN1B LMNA 2319/4885PNLIP 3799/4885TDP1 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.